Physician profile
Laura A Both
NPI 1356564447
$2,749.45
in general payments reported to CMS, 2019-2025
39 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $237 · 2021: $372 · 2022: $438 · 2023: $512 · 2024: $531 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,435 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,434.94 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $434.59 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $314.42 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $222.22 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $184.01 | 2023-2025 | |
| Lilly USA, LLC | $142.76 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.67 | 2019-2025 | Jardiance |
| Abbott Laboratories | $97.48 | 2023-2025 | Freestyle Insulinx, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $93.22 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $85.61 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.42 | 2019-2023 | Trintellix |
| Dexcom, INC. | $63.76 | 2022-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.14 | 2019-2023 | Trulance, Xifaxan |
| Supernus Pharmaceuticals, INC. | $58.53 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.11 | 2024-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $51.45 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $46.52 | 2024-2025 | Fluad, Flucelvax |
| Exact Sciences Corporation | $45.90 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $45.63 | 2019-2020 | |
| Genentech USA, INC. | $45.42 | 2019-2020 | |
| Amgen INC. | $44.55 | 2019-2024 | Evenity, Prolia |
| Eisai INC. | $39.81 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $39.78 | 2021-2022 | |
| Organon LLC | $38.32 | 2024-2025 | Nexplanon |
| Novartis Pharmaceuticals Corporation | $38.04 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $36.79 | 2023-2024 | Vaxneuvance, Capvaxive, Vaxelis |
| Allergan, INC. | $33.83 | 2020 | |
| Biogen, INC. | $30.46 | 2023 | |
| Glaxosmithkline, LLC. | $30.26 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $24.73 | 2019 | |
| Xeris Pharmaceuticals, INC. | $24.71 | 2022 | |
| Mylan Specialty L.P. | $20.62 | 2023 | Yupelri |
| Paratek Pharmaceuticals, INC. | $19.52 | 2023 | Nuzyra |
| Inspire Medical Systems, INC. | $17.37 | 2023 | Inspire |
| Avanir Pharmaceuticals, INC. | $17.24 | 2020 | |
| Esperion Therapeutics, INC. | $16.74 | 2021 | |
| Insulet Corporation | $15.17 | 2021 | |
| Lundbeck LLC | $12.99 | 2023 | Rexulti |
| Amarin Pharma, INC. | $12.96 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Both listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.